FMS Earnings Date: Nov 3, 2026 — Fresenius Medical Care AG & Co. KGaA
NYSE · Healthcare · Medical Care Facilities
Updated
When is FMS's next earnings date?
Fresenius Medical Care AG & Co. KGaA (FMS) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026 at 6:00 AM ET (before market open). The consensus estimate is EPS of $0.65 on revenue of $5.54B.
How did FMS do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q2 2026), Fresenius Medical Care AG & Co. KGaA posted EPS of $0.66 versus the $0.64 estimate, a beat of 3.1%. Revenue was $5.65B against a $5.72B estimate. The stock's 1-day post-earnings move was -1.6%.
How much does FMS stock move after earnings?
FMS beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.5% (up or down) in the day after earnings.
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | 0.64 | 0.66 | +3.12% | $5.65B | ✅ Beat | -1.56% | -5.42% | -11.38% |
| 2026-05-05 | Q1 2026 | 0.59 | 0.53 | -10.17% | $5.40B | ❌ Miss | -10.84% | -3.95% | -5.17% |
| 2026-02-24 | Q4 2025 | 0.67 | 0.84 | +25.37% | $5.90B | ✅ Beat | -7.86% | -4.55% | -10.41% |
| 2025-11-04 | Q3 2025 | 0.59 | 0.64 | +8.47% | $5.71B | ✅ Beat | -7.80% | -10.06% | -10.57% |
| 2025-08-05 | Q2 2025 | 0.50 | 0.52 | +4.00% | $5.32B | ✅ Beat | -2.10% | -3.34% | -2.35% |
| 2025-02-25 | Q4 2024 | 0.40 | 0.49 | +22.50% | $5.43B | ✅ Beat | +0.58% | +1.03% | +4.90% |
| 2024-11-05 | Q3 2024 | 0.38 | 0.45 | +18.42% | $5.23B | ✅ Beat | +1.41% | +6.69% | +17.20% |
| 2024-07-30 | Q2 2024 | 0.37 | 0.38 | +1.89% | $5.13B | ✅ Beat | -3.60% | -7.82% | -3.76% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY23 · $11.89B total
| Segment | Share | Revenue | YoY | Q4 FY14 | Q1 FY23 | Q2 FY23 | Q4 FY23 |
|---|---|---|---|---|---|---|---|
| Health Care Services | 66.1% | $7.85B | — | — | $3.71B | $3.83B | $7.85B |
| Health Care Products | 33.9% | $4.04B | — | — | $14.9M | $9.2M | $4.04B |
By region
FY2025 · $14.68B total · annual
| Segment | Share | Revenue | YoY | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| United States | 96.6% | $14.18B | — | — | — | — | — |
| Germany | 3.4% | $494.6M | +3.3% | — | — | — | $487.3M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.